[Intravesical perfusion of recombinant adeno-associated virus-endostatin in treatment of bladder cancer: experiments with mice].
OBJECTIVE
To study the anti-tumor effect of intravesical perfusion of recombinant adeno-associated virus-endostatin (rAAV-ES) in treatment of bladder cancer.


METHODS
Forty-five C57BL/6 mice underwent intravesical perfusion of mouse bladder cancer cells of the line MB49 so as to establish orthotopic murine bladder cancer models and were divided into 3 equal groups, 3 days later to undergo intravesical perfusion of rAAV-ES, rAAV-EYFP, and PBS respectively once per week for 6 times. The anti-tumor effect of rAAV-ES on the tumor bearing mice was studied.


RESULTS
The tumor weight of the rAAV-ES group was (145 +/- 30) mg, significantly lighter than those of the rAAV-EYFP and PBS groups [(250 +/- 32) mg and (250 +/- 30) mg respectively, both P < 0.05]. The survival time of the rAAV-ES-treated mice was (46 +/- 7) d, significantly longer than those of the rAAV-EYFP- and PBS-treated groups [(38 +/- 7) d and (38 +/- 6) d respectively, both P < 0.05].


CONCLUSIONS
An effective biologic agent in bladder cancer gene therapy, intravesical treatment with rAAV-ES inhibits the angiogenesis, thus inhibiting the tumor formation and progression.
Lu
Bing-Xin
BX
Tianjin Urological Surgery Institute, Tianjin 300211, China. bingxinl@126.com
Han
Rui-Fa
RF
Tang
Yang
Y
Lei
Ming-de
MD
Li
Sheng-Zhi
SZ
D000283:Administration, Intravesical; D000818:Animals; D000229:Dependovirus / Q000235:genetics*; D043169:Endostatins / Q000235:genetics / Q000627:therapeutic use*; D005260:Female; D015316:Genetic Therapy / Q000379:methods*; D051379:Mice; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000628:therapy; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D043169:Endostatins